Novo Nordisk stock slips after Berenberg downgrade as guidance and competition reshape the outlook

Novo Nordisk stock faces pressure after a broker downgrade and a post-guidance pullback, even as 2026 revenue and earnings estimates rise and obesity-drug demand expands in Europe.

Novo Nordisk A/S (ISIN DK0062498333) stock is trading below recent highs as of August 12, 2026, with the ADR around $46.42 on the New York Stock Exchange after a series of guidance updates and a fresh broker downgrade tied to rising competition in diabetes and obesity drugs.

Broker downgrade hits sentiment

According to a report from Investing.com dated August 12, 2026, Novo Nordisk Class B shares fell 3.4% in Copenhagen to trade at DKK 296.7 after Berenberg downgraded the stock from Buy to Hold and cut its local price target to DKK 305 from DKK 325, with the ADR target reduced to $47 from $50.

The same report notes that this move pushed the stock to a session low of DKK 296.6, well below its 52-week high of DKK 410, underscoring how far the shares have retreated from their peak as investors reassess near-term upside relative to stronger competition and valuation.

Guidance raised but shares sold off

Despite the downgrade, fundamental expectations for 2026 have been moving higher. As highlighted by Yahoo Finance coverage of the Berenberg call dated August 12, 2026, the broker raised its 2026 revenue estimate by 2.9% to DKK 296.18 billion and lifted recurring EPS by 10.8% to DKK 23.12, even as it turned more cautious on the stock.

A separate live-news piece from Mitrade dated August 13, 2026 points out that Novo Nordisk raised its full-year sales guidance on August 4, 2026, narrowing its projected annual decline from 8% to 3% at the midpoint, yet NVO shares still dropped roughly 6% that day as investors took profits and weighed the competitive landscape.

For US investors looking at valuation, an analysis from Zacks dated August 12, 2026 notes that Novo Nordisk shares trade at 14.08 times forward earnings versus 18.91 for the broader industry, and well below the company’s five-year mean multiple of 29.20, suggesting that the post-guidance and post-downgrade pullback has compressed the earnings multiple materially.

Market data and dividend context

On the US market, quote data compiled by TradingKey for NVO show the ADR at $46.415, down 1.60% on the August 12, 2026 close, with total market capitalization around $155.53 billion in USD terms, placing Novo Nordisk among the larger global healthcare names.

A related TradingKey analysis in German notes that, by the time of its editorial deadline, the ADR was still down 8.84% at $47.05, illustrating how the stock has remained under pressure over recent sessions rather than staging an immediate rebound from the downgrade and guidance news.

Dividend figures compiled by MarketBeat as of August 13, 2026 indicate that Novo Nordisk’s annual dividend on NVO shares is $1.75 per ADR, corresponding to a dividend yield of 3.76%, with the next ex-dividend date scheduled for August 17, 2026 and the next payment of $0.5786 per share due on August 25, 2026.

For investors, this means that the stock’s pullback has come even as forward revenue estimates and recurring EPS forecasts for 2026 rise and a mid-single-digit yield is on offer, highlighting the tension between improving fundamentals and concerns over competition from Eli Lilly and other players in the GLP-1 space.

Wegovy and expanding obesity coverage

The medium-term story for Novo Nordisk continues to hinge on its GLP-1-based obesity drug Wegovy and related diabetes therapies such as Ozempic. Recent policy developments in Europe point to growing reimbursed demand for these medicines among severely obese patients.

A healthcare-policy article from Pharmaphorum dated August 13, 2026 reports that France’s Health Minister has said the country is the first in the EU to provide reimbursement coverage for weight-loss therapies including Novo Nordisk’s Wegovy, with limited coverage approved for people with severe obesity.

The same coverage estimates that the cost of providing Wegovy and Eli Lilly’s rival drug Mounjaro will be around €100 million per year, with a target population of around one million people who either have a body mass index of 35 with a weight-related comorbidity such as heart disease or a BMI of at least 40.

For Novo Nordisk, this French decision adds to existing reimbursement pathways in markets such as the UK, where the NHS already covers Wegovy for some patients, and supports the longer-term revenue trajectory for obesity drugs even as short-term stock performance reacts to competitive pressures and guidance nuances.

Shares and US trading context

On the US side, Novo Nordisk’s ADR (ticker NVO) trades on the New York Stock Exchange, giving US investors direct access to the Danish drugmaker’s equity alongside domestic peers. Market data from TradingKey indicate that, as of the August 12, 2026 close at 4:00 p.m. ET, the NVO ADR stood at $46.415, down 1.60% on the day.

This price level sits significantly below the Copenhagen 52-week high of DKK 410 cited by Investing.com, and alongside the 3.4% one-day drop to around DKK 296.7 reported on August 12, 2026, underscores a period of consolidation following a strong run driven by GLP-1 demand.

In valuation terms, the Zacks analysis suggesting a forward price-earnings multiple of 14.08 versus 18.91 for the industry and below the company’s five-year mean of 29.20 indicates that Novo Nordisk stock currently combines elevated earnings expectations with a discount to its historical valuation range, implying that sentiment rather than fundamentals has driven much of the recent weakness.

Ozempic, Wegovy, and Novo Nordisk’s product engine

Beyond high-level guidance and analyst views, the core of Novo Nordisk’s business model is its GLP-1-based portfolio, including type 2 diabetes treatment Ozempic and obesity therapy Wegovy. These products have transformed the revenue mix and positioned the company at the center of a global debate over metabolic health, cardiovascular risk reduction, and healthcare-cost management.

Ozempic, a semaglutide-based weekly injectable, was initially approved for type 2 diabetes but has seen off-label interest for weight loss, while Wegovy, a higher-dose formulation of semaglutide, is specifically indicated for chronic weight management in adults with obesity or overweight plus weight-related comorbidities. As coverage expands, these drugs support Novo Nordisk’s guidance and the rising 2026 revenue and EPS estimates highlighted by Berenberg.

Novo Nordisk stock and current price context

As of the August 12, 2026 close on the New York Stock Exchange at 4:00 p.m. ET, Novo Nordisk’s NVO ADR traded at $46.415, reflecting a 1.60% decline on the day and a market capitalization of roughly $155.53 billion in USD terms, based on TradingKey data, with the shares sitting well below the Copenhagen 52-week high of DKK 410 cited in recent coverage.

Novo Nordisk stock facts

• Company: Novo Nordisk A/S
• ISIN: DK0062498333
• Ticker: NVO
• Exchange: New York Stock Exchange (ADR)
• Price (as of August 12, 2026, 4:00 p.m. ET): $46.42 USD
• Market cap: $155.53 billion (as of August 12, 2026)
• Sector / Industry: Health Care - Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: not yet officially scheduled